Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

63.22EUR
25 Apr 2018
Change (% chg)

€-0.68 (-1.06%)
Prev Close
€63.90
Open
€63.30
Day's High
€63.46
Day's Low
€62.24
Volume
1,632,753
Avg. Vol
1,526,640
52-wk High
€80.07
52-wk Low
€58.96

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

BRIEF-Fresenius says believes that Akorn lawsuit is without foundation

* AKORN, INC. SUES FRESENIUS FOR CONSUMMATION OF MERGER AGREEMENT AFTER ITS TERMINATION BY FRESENIUS

23 Apr 2018

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

23 Apr 2018

Fresenius shares gain after it ditches Akorn takeover

FRANKFURT, April 23 Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business.

23 Apr 2018

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT Fresenius said on Monday it would not seek to take over Akorn at more favorable terms, after it terminated the agreement to acquire the U.S. generic drugmaker on Sunday.

23 Apr 2018

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT, April 23 Fresenius said on Monday it would not seek to take over Akorn at more favourable terms, after it terminated the agreement to acquire the U.S. generic drugmaker on Sunday.

23 Apr 2018

Fresenius pulls out of Akorn takeover over data integrity

BERLIN German healthcare group Fresenius SE said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drug maker.

23 Apr 2018

UPDATE 2-Fresenius pulls out of Akorn takeover over data integrity

* Akorn says it disagrees with accusations (Adds Akorn statement)

23 Apr 2018

BRIEF-Akorn Issues Statement In Response To Fresenius Seeking To Terminate Merger

* AKORN INC ISSUES STATEMENT IN RESPONSE TO FRESENIUS KABI’S ANNOUNCEMENT THAT IT IS SEEKING TO TERMINATE THE DEFINITIVE MERGER AGREEMENT

23 Apr 2018

BRIEF-Fresenius SE & Co. KGaA Fresenius Terminates Merger Agreement With Akorn

* DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS TERMINATES MERGER AGREEMENT WITH AKORN Source text for Eikon: Further company coverage:

22 Apr 2018

Fresenius pulls out of Akorn takeover over data integrity

BERLIN, April 22 German healthcare group Fresenius SE said it had decided to pull out of its planned acquisition of Akorn after its own investigation found data integrity breaches at the U.S. generic drug maker.

22 Apr 2018

Earnings vs. Estimates